Anchiano (rebranded from BioCancel) focused on the development of clinical therapies for the treatment of non-muscle-invasive bladder cancer, advanced malignant neoplasms, metastatic lung cancer and metastatic liver cancer. Anchiano merged with Chemomab Therapeutics in 2021 to develop lead compound CM-101, a first-of-its-kind anti-CCL24 antibody, into advanced clinical development for fibrosis-related diseases.
